Study: Post 2
6. Developments and Announcements:
The formation of "BETA"-Date 9/6/2000:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=163078
Date: 6/8/2001: Phytotherapy Technology Pty Ltd is a 25% shareholder in the company's subsidiary company Eiffel Research & Development Pty Ltd (formerly Bioactive Enhancement Technologies Pty Ltd)
Phase II clinical trials of its patented ZINC MONOGLYCEROLATE (ZMG) by Central Clinical Ltd of London had shown positive results against existing hydrocortisone treatment of Eczema.-Date 9/6/2000:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=163073
The name "Pharmaction Holdings Limited" was changed "Eiffel Technologies Limited" - Date 20/12/2000.
(a) Sheffield Pharmaceuticals Inc to apply Eiffel's patent pending technology- Date 21/11/2001:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=184044
(b) Amarin Corporation contract-Date 17/5/202:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=190416
Amarin's positive statement-Date 20/5/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=190480
Eiffel to acquire 100% of Eiffel Research and Development Pty Ltd (ERD)-Date 29/7/2002.
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=192759
(c) Profile Therapeutics plc (LSE: PTP), and Eiffel Technologies agreement- Date 1/7/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=191861
Investors Update-Date 29/7/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=192753
Breakthrough insulin study -Date15/8/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=193502
Announces the formation of its world-class Scientific Advisory Board-Date 8/10/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=195945
BattellePharma advised Eiffel that as the result of a refocus of its research and development investments, it will not continue the combined research activities with Eiffel-Date 12/11/2002:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=197670
(d) Aradigm Corporation agreement-Date: 31/3/03:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=202713
(e) Agreement for its core technology with an unnamed major pharmaceutical company. Looking into NASDAQ listing- Date: 17/4/03:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=203383
(f) Oriel Therapeutics Inc. Agreement. Date: 18/7/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=206411
(g) Meridica (UK) Agreement-Date 8/8/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=207130
(h) Agreement with a large US-based drug delivery company to develop an inhalable form of insulin and to undertake pre-clinical research and development using product modified through Eiffel’s proprietary supercritical fluid (SCF) technology. Date 4/9/2003:
http://stocknessmonster.com/news-item?S=EIF&E=ASX&N=208279
Recent articles about Eiffel:
http://www.eiffeltechnologies.com.au/html/news_articles.asp#bbyl
NB: (a) to (h), a total of 8 agreements in existence.
Gerry
End of study
- Forums
- ASX - By Stock
- EIF
- + data and comment +
EIF
eiffel technologies limited
+ data and comment +, page-2
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EIF (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online